title: Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
abstract: Does a breast cancer diagnosis impact ovarian function in the setting of fertility preservation?
  
  
  
  Ovarian reserve and ovarian stimulation outcomes are similar in patients with a new diagnosis of breast cancer and patients undergoing elective fertility preservation.
  
  
  
  Prior studies, with small study populations, lack of controlling for individual differences in ovarian reserve and infertile controls, have reported conflicting outcomes for cancer patients undergoing ovarian stimulation for fertility preservation.
  
  
  
  This retrospective cohort analysis included 589 patients undergoing ovarian stimulation for fertility preservation between 2009 and 2015.
  
  
  
  Women with a recent breast cancer diagnosis (n = 191) and women desiring elective fertility preservation (n = 398) underwent ovarian stimulation with an antagonist protocol at an academic medical center. The aromatase inhibitor letrozole was administered to breast cancer patients with estrogen-sensitive disease.
  
  
  
  Baseline antral follicle count (AFC) was not different between the breast cancer patients and controls (15.4 ± 10.4 [mean ± SD] vs 15.4 ± 10.0, P = NS), even after categorization by age. Total (19.4 ± 0.9 [mean ± SEM] vs 17.0 ± 0.5, P = NS) and mature (MII) oocytes retrieved (13.7 ± 0.7 vs 13.2 ± 0.4, P = NS), adjusted for age, BMI and total gonadotropin dose, were also similar between the two groups. Letrozole use was associated with a decreased maturity rate (MII/total oocytes retrieved) compared to elective cryopreservation (0.71 ± 0.01 vs 0.77 ± 0.01, P < 0.001), although the mature oocyte yield [MII/AFC] was comparable (1.01 ± 0.06 vs 0.93 ± 0.03, P = NS).
  
  
  
  The single center design may impact generalizability. Additionally, the lack of subsequent embryo and pregnancy data is an inherent weakness.
  
  
  
  In females, a breast cancer diagnosis does not impact gonadal function as measured by AFC or ovarian stimulation outcomes. Breast cancer patients should be counseled that their response to ovarian stimulation for fertility preservation is similar to that of patients undergoing elective oocyte cryopreservation.
  
  
  
  None.
  
  
  
  N/A.
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA94143, USA.
authors.forename: Molly M
authors.initials: MM
authors.lastname: Quinn
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA94143, USA.
authors.forename: Hakan
authors.initials: H
authors.lastname: Cakmak
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA94143, USA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Letourneau
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA94143, USA.
authors.forename: Marcelle I
authors.initials: MI
authors.lastname: Cedars
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA94143, USA.
authors.forename: Mitchell P
authors.initials: MP
authors.lastname: Rosen
mesh_terms: D000328:Adult; D001943:Breast Neoplasms; D015925:Cryopreservation / Q000379:methods; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D006801:Humans; D065851:Ovarian Reserve; D010062:Ovulation Induction / Q000379:methods*; D012189:Retrospective Studies
keywords: breast cancer; elective cryopreservation; fertility preservation; letrozole; oocyte cryopreservation; ovarian reserve